Incretin hormone-targeting dipeptidyl peptidase-4 (DPP-4) inhibitors are an important class of agents indicated for the management of type 2 diabetes mellitus T2DM that owe their significant glucose-lowering effect to up-regulated endogenous incretin levels [110]. Here, DPP4 is linked to diabetes mellitus.